Alebund Pharmaceuticals (Jiangsu) Limited (HKG:9637)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
28.96
-1.00 (-3.34%)
Last updated: Jul 16, 2026, 10:39 AM HKT

HKG:9637 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024
Period Ending
Dec '25 Dec '24
30.566.53
Revenue Growth (YoY)
368.29%-
Cost of Revenue
17.114.14
Gross Profit
13.452.39
Selling, General & Admin
287.6377.28
Research & Development
372.57235.37
Operating Expenses
660.21312.65
Operating Income
-646.76-310.27
Interest Expense
-110.55-29.38
Interest & Investment Income
1.430.57
Earnings From Equity Investments
-2.820
Currency Exchange Gain (Loss)
-0.130.05
Other Non Operating Income (Expenses)
5.153.89
EBT Excluding Unusual Items
-753.67-335.13
Gain (Loss) on Sale of Investments
1.95-
Gain (Loss) on Sale of Assets
-0.1-0
Pretax Income
-751.82-335.13
Earnings From Continuing Operations
-751.82-335.13
Minority Interest in Earnings
1.789.1
Net Income
-750.04-326.03
Net Income to Common
-750.04-326.03
Shares Outstanding (Basic)
244272
Shares Outstanding (Diluted)
244272
Shares Change (YoY)
-10.08%-
EPS (Basic)
-3.07-1.20
EPS (Diluted)
-3.07-1.20
Free Cash Flow
-389.51-480.52
Free Cash Flow Per Share
-1.59-1.77
Gross Margin
44.00%36.55%
Operating Margin
-2116.64%-4755.03%
Profit Margin
-2454.63%-4996.57%
Free Cash Flow Margin
-1274.74%-7364.34%
EBITDA
-607.19-303.36
D&A For EBITDA
39.576.91
EBIT
-646.76-310.27